Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxane-platinum plus cetuximab followed by avelumab plus cetuximab maintenance in first-line recurrent or metastatic head and neck squamous cell carcinoma
2023-510559-41-00Phase 2Authorised
- Sponsor
- GORTEC
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab, cetuximab, paclitaxel, cisplatin and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Primary endpoint: Overall survival. Planned start Nov 2024; status: authorised.
02
Drugs
avelumabcetuximabpaclitaxelcisplatincarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-510559-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510559-41-00.